Pharmacia Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Stockholm Sweden (1911)
Status: Acquired by Pfizer (2003)

Organization Overview

First Clinical Trial
1999
NCT00200174
First Marketed Drug
1979
phenytoin (mesantoin)
First NDA Approval
1992
lomefloxacin (maxaquin)
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PHARMACIA | Pharmacia Corporation | Pharmacia GmbH, Erlangen, Germany | Pharmacia Pharmaceutical Company | PHARMACIA SAS | Pharmacia (v1) | Pharmacia (v2)

Active Ingredients

Marketed Drugs (11)

Key: Pharmacia (10) Acquired (1)

amlodipine (norvasc) (2004)

atorvastatin (lipitor) (2004)

dalteparin (fragmin) (1994 NDA)

dexrazoxane (zinecard) (NDA)

epirubicin (ellence) (1999 NDA)

linezolid (zyvox) (NDA)

lomefloxacin (maxaquin) (1992 NDA)

pegvisomant (somavert) (2003)

phenytoin (mesantoin) (1979)

somatropin (protropin) (1995)

terodiline (NDA)

Drugs in Phase 4 Trials (6)

Key: Pharmacia (4) Acquired (2)

arginine (1 trial)

ethambutol (myambutol) (2 trials)

nicotine (nicorette) (1 trial)

oxycodone (oxycontin) (1 trial)

pregabalin (lyrica) (1 trial)

rifabutin (mycobutin) (6 trials)

Drugs in Phase 3 Trials (29)

Key: Pharmacia (5) Acquired (24)

carboplatin (paraplatin) (6 trials)

celecoxib (celebrex) (7 trials)

cisplatin (platinol) (3 trials)

clarithromycin (biaxin) (1 trial)

corn oil (1 trial)

cyclophosphamide (cytoxan) (4 trials)

darbepoetin alfa (aranesp) (1 trial)

delavirdine (rescriptor) (9 trials)

didanosine (videx) (6 trials)

doconexent (1 trial)

epirubicin (ellence) (6 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (3 trials)

gemcitabine (gemzar) (2 trials)

icosapent ethyl (vascepa) (1 trial)

irinotecan (Camptosar) (11 trials)

lamivudine (epivir) (3 trials)

leflunomide (arava) (3 trials)

leucovorin (2 trials)

methylprednisolone (medrol) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (1 trial)

paclitaxel (taxol) (5 trials)

prednisone (meticorten) (2 trials)

procarbazine (matulane) (1 trial)

romiplostim (nplate) (4 trials)

tranexamic acid (cyklokapron) (1 trial)

vitamin e (1 trial)

zidovudine (retrovir) (14 trials)

Drugs in Phase 2 Trials (16)

Key: Pharmacia (3) Acquired (13)

atevirdine (4 trials)

bevacizumab (avastin) (1 trial)

cytarabine (cytosar-u) (1 trial)

docetaxel (taxotere) (3 trials)

emivirine (1 trial)

exemestane (aromasin) (2 trials)

glycovir (1 trial)

hydroxyurea (hydrea) (1 trial)

imatinib (gleevec) (1 trial)

miglustat (zavesca) (3 trials)

mitomycin (mutamycin) (1 trial)

sargramostim (leukine) (2 trials)

stavudine (zerit) (2 trials)

tamoxifen (nolvadex) (1 trial)

thymus humoral factor (1 trial)

zalcitabine (hivid) (2 trials)

Drugs in Phase 1 Trials (5)

Key: Pharmacia (2) Acquired (3)

alvircept sudotox (2 trials)

lamotrigine (lamictal) (1 trial)

rivaroxaban (xarelto) (1 trial)

somatropin (protropin) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (9)

Key: Pharmacia (4) Acquired (5)

capecitabine (xeloda) (1 trial)

clindamycin (cleocin) (1 trial)

indinavir (crixivan) (3 trials)

nelfinavir (viracept) (1 trial)

platelets (1 trial)

pyrimethamine (daraprim) (1 trial)

raloxifene (evista) (1 trial)

thrombopoietin (1 trial)

ubiquinone (1 trial)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial APIs: 65